Percutaneous coronary intervention in Acute myocardial infarction Study) trial was the landmark study, which established the role of thrombus aspiration in reducing no-reflow, improving myocardial blush (MB), ST-segment resolution and mortality at 1 year. 3, 4 However, subsequent studies have shown conflicting results. [5] [6] [7] [8] [9] [10] [11] We sought to evaluate the clinical variables and outcomes associated with the performance of thrombectomy in STEMI patients.
Methods

Data and Clinical Definitions
Patients included in this study were evaluated from a singlecenter STEMI database/registry. This registry was developed as part of a quality improvement and outcome monitoring device. We defined STEMI to be present if the initial electrocardiogram (EKG) showed at least 1-mm ST-segment elevation (> 2-mm ST-segment elevation in right precordial leads, V1-V3) in two or more contiguous leads in standard EKG at the time of the emergency room arrival or in the EKG done by paramedics; in conjunction with ischemic symptoms. All patients who undergo PCI are entered into this prospective registry. Standardized information is collected which includes demographic profile, clinical characteristics, ischemic time, angiographic characteristics and procedural details, laboratory data, hospitalization course, and subsequent clinical follow-up. Ethnicity is self-identified and is finally determined in conjunction with the country of origin. All of these patients routinely receive 325 mg aspirin, 600 mg of clopidogrel, and 80 mg of atorvastatin in the emergency room. Cardiac enzymes were drawn at the time of presentation in the emergency room and subsequently in 6 to 8 hour intervals. Due to the change in hospital's protocol for checking troponin I to troponin T we only report creatine kinase (CK) and CK-MB fraction. Guideline-directed medical therapy is prescribed for all patients, including 81to 325 mg aspirin, 75 mg clopidogrel, and statins, β blocker, and angiotensinconverting enzyme inhibitor. Patients are routinely contacted 30 days after the discharge. Clinical outcomes are ascertained via telephonic contact with the patient, family, or physician. In addition, the social security death index is reviewed for mortality detection and confirmation. Predischarge left ventricular function (LVEF) is determined by a follow-up transthoracic echocardiogram (done between 3 and 7 days) in all patients. The LVEF is determined using the Simpson biplane formula, according to the recommendations of the American Society of Echocardiography. PCI is performed according to the best recommended contemporary clinical practice. All patients received bivalirudin during the procedure. The decision on the adjunctive use of glycoprotein IIb/IIIa inhibitors, intra-aortic balloon pump (IBMP), and mode of revascularization: surgical versus percutaneous, bare metal versus drug eluting is at the discretion of the treating interventional cardiologist. The thrombolysis in myocardial infarction (TIMI) grade flow is defined as follows: TIMI 0 flow (no perfusion): absence of any antegrade flow beyond a coronary occlusion; TIMI 1 flow (penetration without perfusion): faint antegrade coronary flow beyond the occlusion, with incomplete filling of the distal coronary bed; TIMI 2 flow (partial reperfusion): delayed antegrade flow with complete filling of the distal territory; and TIMI 3 flow (complete perfusion): normal flow which fills the distal coronary bed completely. MB was graded as described by Van 
Clinical Outcomes/Endpoints
We compared postrevascularization TIMI grade flow in the culprit epicardial vessels, MB score, peak serum cardiac enzyme level, resolution of the elevated ST segments on EKG, 30 day reinfarction, and all-cause mortality between the groups. We defined complete revascularization as grade 3 TIMI flow with a MB score of 2 or greater. EKGs were assessed for ST-segment resolution within 90 minutes after PCI was performed. We defined early complete resolution if ST segments went down by > 70% as compared with the presentation EKG. 
Statistical Methods
Predictors of Thrombectomy
On multivariate analysis anterior infarction (OR: 1.7, 95% CI: 
Clinical Outcomes and Endpoints Enzymatic Infarct Size
Patients who underwent thrombectomy had higher peak serum cardiac enzymes (CPK: 2,796 [2, 575] 
Discussion
The present study is one of the few studies 13-17 which describe the role of routine thrombectomy on enzymatic infarction size, reinfarction, and mortality in a relatively large cohort of unselected STEMI patients who underwent PCI. In our retrospective cohort, we observed that patients with anterior wall myocardial infarction and hemodynamic instability were more likely to undergo mechanical thrombectomy during primary PCI. The mortality and re-infarction rates were comparable between the group who underwent thrombus aspiration and those who underwent conventional primary PCI. We also observed that patients who received thrombectomy sustained larger enzymatic infarction size and had less early ST segment resolution. Concurrent with existing literature, clinical outcomes in our STEMI cohort was influenced by age, presence of diabetes mellitus and ischemic duration. In STEMI patients, mechanical reperfusion or primary PCI leads to rapid restoration of epicardial flow, which has been associated with improved clinical outcomes including survival. 18, 19 However, the patency of epicardial flow does not necessarily indicate adequate myocardial perfusion. This could be explained by microvascular occlusion due to distal embolization of atherothrombotic material during mechanical reperfusion. Most recent study, the TASTE (Thrombus Aspiration during ST-Elevation myocardial infarction) also concluded that manual thrombus aspiration before PCI had no significant effect on the primary endpoint of all-cause mortality at 30 days. The neutral outcome was consistent in all patient subgroups, regardless of baseline clinical or angiographic characteristics.
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Routine thrombectomy is not frequently performed in the United States, but there is an increasing temporal trend. An analysis of the CathPCI registry data showed that thrombectomy was performed in only 19% of STEMI patients between July 2009 and December 2010. 32 Use of manual thrombectomy were more likely in patients with preprocedural TIMI 0/1 flow, younger age, saphenous vein graft, glycoprotein IIB/IIIA inhibitor use, and single vessel disease. Similar results were observed in our data, only patients with anterior infarction (OR: 1.7), preprocedural TIMI 0/1 flow (OR: 8.6), and IABP use (most likely for hemodynamic instability or decompensated heart failure) (OR: 0.4) were more likely to undergo thrombectomy. The difference in results regarding graft and GP IIB/IIIA inhibitor utilization could be attributed to lower rates of graft-related infarction and glycoprotein IIB/IIIA use in our cohort. Despite, the interventional cardiologists bias toward using thrombectomy in TIMI 0/1 flow patients, we did not find a significant interaction between preprocedural TIMI flow and the impact of thrombectomy on mortality or reinfarction rates. Postprocedural TIMI 3 flow was also similar between groups. This could be partly explained by improvements in the management of STEMI patients by the introduction of a newer generation of drug eluting stents, or the use of better pharmacotherapy including the early introduction of statins, angiotensin-converting enzyme inhibitors, optimal dual antiplatelet therapy, and cardiac rehabilitation. Our study has several limitations. First, it represents a single-center experience using retrospectively collected data. However, our data set is representative of day-to-day community practices for the management of STEMI. Second, while the study population is modest in size, it remains comparable to several major studies undertaken. 2, 3, 5, 6 Nevertheless, mortality was seen in only 30 patients. The patients with failed revascularization and those who died before completion of revascularization were excluded due to lack of data in our registry. This additional information might have affected the overall mortality and hence the interpretation. Third, we did not evaluate thrombus burden in these patients. However, the TAPAS trial 3 randomized patients to thrombectomy irrespective of angiographic characteristics and findings from the TASTE trial also points toward a lack of association between thrombus characteristics and clinical outcomes. Finally, we were not able to include subsequent PCI, CABG, and nonfatal MI beyond 30 days due to lack of proper documentation. Despite these limitations, the results from this study are clinically relevant and should generate further discussion and motivate future prospective studies.
Conclusion
Our real-world observation of thrombectomy utilization, found that higher risk STEMI patients with hemodynamic instability are more likely to undergo thrombectomy during primary PCI in an uncontrolled clinical setting.
